Gilead inks non-exclusive licensing pacts with 5 generic drug-makers
Category: #health  | By Mateen Dalal  | Date: 2020-05-13 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Gilead inks non-exclusive licensing pacts with 5 generic drug-makers

Gilead Sciences, an American biopharmaceutical company, has recently inked non-exclusive licensing pacts with 5 India- and Pakistan-based generic drug-makers. These licensing agreements have been made to increase the supply of remdesivir, Gilead’s experimental COVID-19 treatment.

The licensing pacts will enable companies, namely Ferozsons Laboratories Ltd., Mylan NV, Hetero Labs Ltd., Cipla Ltd., and Jubilant Life Sciences Ltd., to manufacture and sell the drug in 127 countries. Gilead stated that these countries consist of low-income, lower-middle income, upper-middle as well as high-income populations. South Africa, Pakistan, North Korea, India, and Afghanistan are among the countries that the company will allow remdesivir production in. The company further added that the licensees or companies will set the prices for their generic products.

The licenses are reportedly royalty-free until the WHO (World Health Organization) declares the termination of the public health emergency posed by COVID-19 pandemic, or the development of a vaccine or other products that are approved to prevent or treat COVID-19 disease. This antiviral drug produced by Gilead received emergency use authorization from the U.S. Food & Drug Administration earlier this month to treat patients that are infected with the coronavirus.

Rising focus on this drug, due to the unavailability of other approved COVID-19 treatment (a respiratory disease caused by coronavirus), has been observed. The company is being analyzed closely on its distribution and pricing of the limited supply of this antiviral drug. Gilead previously reported that it was negotiating with various generic drug-makers in Pakistan and India regarding the long-term licenses to offer the drug in developing countries. It has also negotiated on offering the technology that support the drug production.

The coronavirus pandemic has reportedly claimed the lives of around 286,000 people globally. To address and combat the spread of this virus, several drug-makers are accelerating the development of a viable vaccine or treatment candidate.

Source credit:

https://zeenews.india.com/world/gilead-ties-up-with-generic-drugmakers-in-india-pakistan-for-coronavirus-covid-19-drug-supply-2283098.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Apollo plans to expand looking at average occupancy surge

Apollo plans to expand looking at average occupancy surge

By Mateen Dalal

Apollo Hospitals Enterprises Ltd., one of India's leading healthcare providers, is reportedly targeting to increase the average occupancy rate in its hospitals to 68-70% for the fiscal year 2024. The company recently announced impressive finan...

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...